{"prompt": "['Amended Clinical Trial Protocol No. 05', '15-Dec-2021', 'GZ402673-EFC13429 - alemtuzumab', 'Version number: 1', '8', 'STUDY TREATMENTS', '8.1', 'INVESTIGATIONAL MEDICINAL PRODUCT(S)', 'Name of the Investigational Medicinal Product (IMP):', 'Alemtuzumab.', 'Pharmaceutical form:', 'Concentrate for solution for infusion (sterile concentrate). Each vial contains 12 mg/1.2 mL of', 'solution.', 'Dose of drug per administration:', 'First course: at Month 0 for 5 consecutive days', 'Calculation of the dose used will be determined based on patient weight taken at the first infusion', 'visit, of the first course, during the physical examination:', 'For patients >50 kg: 12 mg/day.', 'For patients <50 kg: 0.24 mg/kg/day.', 'Second course: at Month 12 for 3 consecutive days', 'Calculation of the dose used will be determined based on patient weight taken at the first infusion', 'visit, of the second course, during the physical examination:', 'For patients >50 kg: 12 mg/day.', 'For patients <50 kg: 0.24 mg/kg/day.', 'Route of administration:', 'IV infusion.', '8.1.1 Administration', 'Alemtuzumab will be administered only after a decision from the Study Investigator.', 'First course: Alemtuzumab will be administered by IV infusions for 5 consecutive days at', 'Month 0 in a supervised medical setting at a dose of:', 'For patients >50 kg: 12 mg/day.', 'For patients <50 kg: 0.24 mg/kg/day.', 'Property of the Sanofi Group - strictly confidential', 'Page 46', 'VV-CLIN-0254406: 5.0']['Amended Clinical Trial Protocol No. 05', '15-Dec-2021', 'GZ402673-EFC13429 - alemtuzumab', 'Version number: 1', 'Second Course will occur 12 months after the first course.', 'Second Course: Alemtuzumab will be administered by IV infusion for 3 consecutive days at', 'Month 12 in a supervised medical setting at a dose of:', 'For patients >50 kg: 12 mg/day.', 'For patients <50 kg: 0.24 mg/kg/day (this equates to 12 mg/day for a 50 kg patient).', '8.1.1.1 Method of preparation at the clinical site', 'Alemtuzumab must be diluted before infusion. The diluted solution must be administered by', 'IV infusion. The infusion duration will be approximately 4 hours starting within 8 hours after', 'dilution. Extend the duration of the infusion if clinically indicated.', 'Additional requirements for alemtuzumab infusion and monitoring during and post infusion are', 'specified in Section 10.1.4 Visit 4/M0/D1 (first course of alemtuzumab) and Section 10.1.10', 'Visit 16/M12 (second course of alemtuzumab).', '8.1.1.2 Special precautions for disposal and other handling', 'The vial contents must be inspected for particulate matter and discoloration prior to', 'administration. Do not use if particulate matter is present or the concentrate is discolored. Do not', 'shake the vials prior to use.', 'For IV administration, withdraw the prescribed amount of alemtuzumab from the vial into a', 'syringe using aseptic technique. Inject into 100 mL of sodium chloride 9 mg/mL (0.9%) solution', 'for infusion or glucose (5%) solution for infusion. This medicinal product must not be diluted', 'with other solvents. The bag must be inverted gently to mix the solution.', 'Alemtuzumab contains no antimicrobial preservatives and, therefore, care must be taken to ensure', 'the sterility of the prepared solution. It is recommended that the diluted product be administered', 'immediately. Each vial is intended for single use only.', 'Any partially used, unused, or damaged drug vials should be disposed of in accordance with local', 'requirements.', '8.2', 'NONINVESTIGATIONAL MEDICINAL PRODUCTS', 'A) Premedications:', 'Day - 1 (day before first IV infusion at each course) in the morning:', '-', 'Oral prednisone/prednisolone 1 mg/kg or 50 mg one dose, whichever is lower, or', 'equivalent,', '-', 'H2 antagonist according to the local label (eg, ranitidine).', 'Property of the Sanofi Group - strictly confidential', 'Page 47', 'VV-CLIN-0254406: 5.0']\n\n###\n\n", "completion": "END"}